Skip to main content

Advertisement

Table 1 Baseline study population characteristics (n = 43)

From: Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial)

Age (yrs)
  median (range) 80 (70 – 92)
Sex (M/F) 36/7
ECOG PS (0/1/2) 0/16/27
Stage (IIIB/IV) 16/27
Smoke (never/past/current) 1/23/19
Serious co-morbid illnesses
  median (range) 3 (0 – 6)
Histology (n/%)
  Squamous cell carcinoma 24/43 (55.8%)
  Adenocarcinoma 11/43 (25.6%)
  Large-cell carcinoma 4/43 (9.3%)
  Undifferentiated 4/43 (9.3%)